Coffee consumption and risk of coronary heart disease: a meta-analysis by Sofi, Francesco et al.
Nutrition, Metabolism & Cardiovascular Diseases (2007) 17, 209e223
www.elsevier.com/locate/nmcdCoffee consumption and risk of coronary
heart disease: A meta-analysis
Francesco Sofi a,d,*, Andrea A. Conti a,b, Anna Maria Gori a,d,
Maria Luisa Eliana Luisi b, Alessandro Casini c,d,
Rosanna Abbate a,d, Gian Franco Gensini a,b
a Department of Medical and Surgical Critical Care and Center for the Study at
Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Diseases
to Develop Novel Therapies, University of Florence, Florence, Italy
b Don Carlo Gnocchi Foundation, IRCCS, Florence, Italy
c Department of Clinical Pathophysiology, Unit of Clinical Nutrition,
University of Florence, Florence, Italy
d Centro Interdipartimentale di Ricerca per la Valorizzazione degli Alimenti (CeRA),
University of Florence, Florence, Italy
Received 27 May 2006; received in revised form 14 July 2006; accepted 22 July 2006
KEYWORDS
Coffee;
Caffeine;
Coronary heart
disease;
Myocardial infarction;
Meta-analysis
Abstract Background and aims: During the past three decades the relationship
between habitual coffee drinking and coronary heart disease (CHD) has been as-
sessed in numerous studies, with conflicting results. The aim of this study was to
systematically examine the data published on the association between habitual
coffee consumption and risk of CHD.
Methods and results: Thirteen caseecontrol and 10 cohort studies were included.
Caseecontrol studies incorporated 9487 cases of CHD and 27,747 controls, and
cohort studies included a total of 403,631 participants that were followed for
between 3 and 44 years. The summary of odds ratios (OR) for the caseecontrol
studies showed statistically significant associations between coffee consumption
and CHD for the highest intake group (>4 cups/day), OR 1.83 (95% CI 1.49e2.24;
P < 0.0001), and for the second highest category (3e4 cups/day), OR 1.33 (95% CI
1.04e1.71; P < 0.0001), while no significant association emerged for low daily cof-
fee intake (2 cups/day), OR 1.03 (95% CI 0.87e1.21; P ¼ 0.45). The analysis of
long-term follow-up cohort studies did not show any association between the con-
sumption of coffee and CHD, with a relative risk (RR) of 1.16 (95% CI 0.95e1.41;
P ¼ 0.14) for the highest category, and 1.05 (95% CI 0.90e1.22; P ¼ 0.57) and
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210 F. Sofi et al.1.04 (95% CI 0.90e1.19; P ¼ 0.60) for the second and third highest categories,
respectively. These results did not differ substantially when controlling for region
of origin, fatal and non-fatal events, year of publication, and number of years of
follow-up.
Conclusions: Despite a significant association between high consumption of coffee
and CHD reported among caseecontrol studies, no significant association between
daily coffee consumption and CHD emerged from long-term follow-up prospective
cohort studies.
ª 2006 Elsevier B.V. All rights reserved.Introduction
Coffee is one of the most widely consumed
beverages in the world. Since early 1970s, coffee
consumption has attracted interest as a potential
health hazard due to the positive association
with coronary heart disease (CHD) reported in
a number of caseecontrol and cohort studies
[1e14]. However, in contrast with these results,
other caseecontrol and cohort studies performed
in different population groups showed negative re-
sults, perhaps indicating that in some of the previ-
ous studies the strong association reported
between coffee consumption and CHD resulted
from inappropriate statistical analysis, i.e. lack
of adjustment for possible confounders [15e28].
To date, the question whether coffee drinking
increases the risk of CHD continues to be contro-
versial. Meta-analyses of the association between
coffee consumption and CHD carried out in the
1990s reported conflicting results within the
different types of studies analysed, as shown by
the positive association with CHD found among
caseecontrol but not among cohort studies. In
1992, Myers and Babinski carried out a meta-
analysis of cohort prospective studies and reported
no influence of coffee on CHD [29]; whereas in
1993, Greenland reported a positive association
with CHD among caseecontrol studies, but not
among prospective cohort studies [30]. The latter
association is supported by the most recent analy-
sis conducted in 1994 by Kawachi et al., which
showed an increased risk of CHD with consumption
of five cups of coffee per day, but only among
caseecontrol studies [31].
Currently, the influence of coffee on the health
of people, is considered of great significance due
to the enormous consumption worldwide. How-
ever, analysing the occurrence of disease in
relation to intake of coffee is difficult, mainly
due to the complexities that arise when trying to
define a coffee beverage. Coffee, as a beverage
made from the extract of coffee beans, is avail-
able in a remarkable variety of different typesthroughout the world, in terms of brewing
method and caffeine content; even within the
same country methods of preparation and drink-
ing preferences differ significantly. This could
partly explain the contrasting results reported in
the literature. Hence, we decided to conduct
a systematic review with meta-analysis of the
available epidemiological studies, both caseecon-
trol and prospective, in order to evaluate if
habitual coffee consumption is associated with
an increased risk of CHD.
Methods
Study selection
We conducted a systematic literature search of
MEDLINE from 1966, EMBASE from 1990, Science
Citation Index from 1994, and the Cochrane Sys-
tematic Review Database up to April 2006, to
identify studies that examined the association
between habitual coffee consumption and CHD,
with an analytical designdeither caseecontrol
(retrospective or nested) or longitudinal. We used
a combined text word and medical subject head-
ings (MeSH) search strategy with the terms ‘coffee’
and ‘caffeine’ in combination with ‘cardiovascular
diseases’, ‘coronary artery disease’, ‘coronary
heart disease’, ‘myocardial infarction’, and ‘acute
coronary syndromes’. We included references
listed in the retrieved articles as well as in review
articles and in meta-analyses. The aim of this study
was to evaluate the possible association between
coffee consumption and occurrence of CHD, with
non-users or the lowest category as a reference.
Hence, to be included in the meta-analysis, studies
had to provide, as primary or secondary outcome,
the association between coffee and CHD, as well as
estimates of associations for the different cate-
gories of coffee consumption, and full information
on study design and participant characteristics.
Our search strategy generated 24 potentially
relevant caseecontrol articles [1,2,5,7e12, 21e23,
Coffee and coronary heart disease 21126,32e42]. Four studies were excluded since they
did not contain sufficient information to enable
an estimate of risk or its standard error to be calcu-
lated for all categories of coffee consumption
[1,33e35]. Five studies were excluded because
they did not report outcomes of interest for this
meta-analysis [36e40], one because it reported
only data for decaffeinated coffee consumption
[41], and another study [8] represented the final
data from a previous paper [7], so only the final
paper was included. Hence, 13 caseecontrol
papers were included in the final analysis [2,5,8e
12,21e23,26,32,42], incorporating 9487 cases of
CHD and 27,747 controls. With regard to cohort
prospective studies, we identified 38 potentially
relevant studies [3,4,6,13e20,24,25,27,28,33,
43e64], of which only 10 satisfied the inclusion cri-
teria [4,14,17,20,24,25,27,28,43]. Seventeen stud-
ies contained insufficient data to enable the
associations between different categories of cof-
fee consumption and CHD to be estimated
[3,6,15,19,33,44e55]. A further six studies reported
outcomes that were not relevant to the present
study [56e61]. In addition, the papers by Martin
et al. [13] and Hakim et al. [62] were excluded
since they studied a population of hypertensives,
and two further studies [63,64] were not included
in this review because they included a category
other than that of very low consumption as a refer-
ence. Finally, papers by Willett et al. [18] and by
Grobbee et al. [16] were replaced by the work of
Lopez-Garcia et al. [27], which included updated
follow-up analyses deriving from the former two
preliminary studies.
Data extraction
All data were independently extracted by two
investigators (F.S. and A.M.G.) through use of
a standardized data extraction tool, and were
entered into separate databases. Data regarding
study design, participant characteristics, country
of origin, adjustment for potential confounders,
measurements of coffee consumption, outcomes,
and estimates of associations, were sought from
each article. Results were compared, and dis-
agreements were resolved by consensus. In cases
in which there was more than one published report
on the same population or group of patients, the
most recent article was selected for analysis.
Statistical analysis
Data were analysed by using Review Manager
(RevMan) software for Windows (version 4.2) by
the Cochrane Collaboration, 2003, and STATA(version 8.2). We distinguished four levels of
coffee consumption: the highest category of con-
sumption (mainly >4 cups per day, except for
Tavani et al. [32] and Kalandidi et al. [10] among
caseecontrol studies, and Lindsted et al. [14]
among cohort studies, where >3 cups per day
was used); the second highest category of coffee
consumption (mainly 3e4 cups per day, excluding
Jick et al. [2] and Rosenberg et al. [8] among
caseecontrol studies, and papers by Klatsky and
colleagues [24,43] among cohort studies, where
a range between 1e5 cups per day was used);
the third highest category of coffee consumption
(mainly 2 cups per day); and the reference cate-
gory (none or <1 cup per day). Studies not report-
ing categories of coffee consumption were
excluded from each analysis to improve compara-
bility with other studies. Thus, among casee
control studies, three studies from the analysis of
the second highest category [10,21,22] and two
from the analysis of the third category [2,9] were
excluded. Similarly, as for cohort prospective stud-
ies, two studies from the comparison of the second
highest category [14,17] and one study from the
analysis of the third category [17] were excluded.
We used the results of the original studies from
multivariable models with the most complete ad-
justment for potential confounders; the confound-
ing variables included in this analysis are shown in
Tables 1 and 2. The analysis was carried out using
a random-effects model that accounts for inter-
study variation and provides a more conservative
estimate than a fixed model. Thus, we calculated
random summary odds ratios (OR) and relative
risks (RR) with 95% confidence intervals (CI) for
caseecontrol and cohort studies, respectively, by
using the inverse-variance method. The potential
sources of heterogeneity were assessed using the
standard chi-square test. In addition, the statistic
I2 was used to investigate heterogeneity by exam-
ining the extent of inconsistency across the study
results. To examine the source of heterogeneity
across studies we conducted sensitivity analyses,
according to some characteristics of the studies
included in the meta-analysis; i.e. the different
region of origin of the studies (Europe/USA), the
year of publication (studies published before and
after the median year of publication of all the
studies combined, i.e. 1995), as well as outcome
measures (fatal, non-fatal events), and number
of years of follow-up within cohort studies (before
and after the median years of follow-up of all the
studies combined, i.e. 15 years).
Funnel plots were performed to assess potential
publication bias, as suggested by Egger et al. [65].
Moreover, to estimate whether publication bias
Adjustment
Age, gender,
history of MI
Age, smoking habit,
hypertension, diabetes,
hypercholesterolemia,
BMI, oral contraceptive
use
Age, smoking habit,
hypertension, diabetes,
hypercholesterolemia,
BMI, physical activity,
alcohol, family history
of MI, education
Age, gender, smoking
habit, hypertension,
diabetes,
hypercholesterolemia,
physical activity, alcohol
.82)
.61)
Age, cholesterol,
diastolic blood pressure,
smoking habit, BMI,
total energy, alcohol
.97)
.97)
.99)
Age, smoking habit,
hypertension, diabetes,
hypercholesterolemia,
BMI, alcohol, family
history of MI, education
Age, smoking habit,
hypertension, diabetes,
family history of MI,
BMI, education, alcohol,
physical activity
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Source, year Country Cases/
controls
Age
(years)
Gender Outcome Coffee
consumption
Adjusted OR
(95%CI)
Jick et al. 1973 [2] USA 440/12319 40e69 M/F MI None 1.00
1e5 cups/day 1.6 (1.3e2.0)
6 cups/day 2.2 (1.6e3.1)
Rosenberg et al.
1987 [8] (final data
of Rosenberg
et al. 1980 [7])
USA 491/1119 30e49 F MI None 1.00
1e4 cups/day 1.0 (0.7e1.3)
5e9 cups/day 1.4 (1.0e2.1)
10 cups/day 2.0 (1.2e3.5)
(5 cups/day) 1.7 (1.2e2.4)
Rosenberg et al.
1988 [9]
USA 1867/1158 25e54 M MI None 1.00
1e2 cups/day 1.4 (1.0e1.9)
3e4 cups/day 1.6 (1.2e2.2)
5e9 cups/day 1.8 (1.3e2.5)
 10 cups/day 2.9 (2.9e4.3)
(5 cups/day) 2.2 (1.6e3.0)
Kalandidi
et al. 1992 [10]
Greece 329/570 <40; >80a M/F CHD <1 cups/day 1.00
1e2 cups/day 1.17 (0.75e1
3 cups/day 2.07 (1.18e3
Brown et al. 1993 [23] Scotland 2074/7494 40e59 M/F CHD None 1.00
1e2 cups/day 0.83 (0.72e0
3e4 cups/day 0.81 (0.68e0
5 cups/day 0.81 (0.67e0
D’Avanzo et al. 1993 [11] Italy 801/792 24e74 M MI Non-use 1.00
1 cup/day 0.8 (0.5e1.2)
2 cups/day 1.3 (0.9e2.0)
3 cups/day 1.8 (1.1e2.7)
4 cups/day 2.5 (1.5.4.1)
5 cups/day 2.6 (1.6e4.2)
Palmer et al. 1995 [5] USA 858/858 45e69 F MI 1 cup/day 1.00
1e2 cups/day 0.9 (0.6e1.3)
3e4 cups/day 0.9 (0.6e1.4)
5e6 cups/day 1.4 (0.8e2.5)
7e9 cups/day 2.1 (0.9e4.9)
10 cups/day 2.5 (1.0e6.5)
(5 cups/day) 1.7 (1.0e1.7)
ay 1.00 Age, BMI, hypertension
day 1.1 (0.48e2.23)
day 2.8 (0.66e3.84)
day 4.0 (0.70e7.96)
ay 5.7 (2.0e26.9)
eek 1.00 Age, gender, smoking habit,
hypertension, family history of
MI, diabetes, BMI, physical activity,
total caloric intake, alcohol
s/day 0.91 (0.58e1.45)
ay 0.84 (0.49e1.42)
ay 1.00 Age, gender, smoking
habit, hypertension,
diabetes, hypercholesterolemia,
BMI, history of MI, alcohol,
physical activity
day 1.4 (0.9e2.1)
s/day 1.1 (0.7e1.7)
s/day 1.6 (1.0e2.5)
ay 1.9 (1.1e3.3)
1.00 Age, gender, smoking habit,
hypertension, diabetes,
hypercholesterolemia, BMI,
alcohol, family history of MI,
education
day 0.69 (0.5e0.86)
day 1.56 (1.1e2.34)
ay 3.1 (1.82e5.26)
ay 1.00 Age, smoking habit, hypertension,
diabetes, dyslipidemia, BMI, study,
education, alcohol, physical
activity, family history of MI
day 1.1 (0.8e1.6)
ay 1.4 (0.9e2.1)
1.00 Age, education, smoking habit,
waist-to-hip ratioay 2.04 (0.28e15.03)
s/day 2.44 (0.31e19.03)
ay 1.72 (0.20e14.46)
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213Rabajoli et al. 1997 [12] Italy 88/136b 35e70 M MI <1 cup/d
1e2 cups/
2e3 cups/
3e4 cups/
>4 cups/d
Sesso et al. 1999 [22] USA 336/337 <76a M/F MI 1 cup/w
>1e3 cup
4 cups/d
Tavani et al. 2001 [21] Italy 507/478 25e79 M/F MI 1 cup/d
1e2 cups/
>2e3 cup
>3e5 cup
6 cups/d
Panagiotakos
et al. 2003 [42]
Greece 848/1078 56e65 M/F ACS None
1e2 cups/
2e4 cups/
>4 cups/d
Tavani et al. 2004 [32] Italy 558/1044 18e79 F MI <1 cup/d
1e3 cups/
>3 cups/d
Azevedo and
Barros 2006 [26]
Portugal 290/364c >40a M/F MI None
2 cups/d
>2e4 cup
>4 cups/d
ACS, acute coronary syndromes; BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarct
a Not otherwise indicated in the study.
b The population study consisted of either non- or former.
c The population study consisted of subjects with a family history of MI.
TS
n
Adjusted
RR (95% CI)
Adjustment
L 1.00 Age, cholesterol,
smoking habitday 1.19 (0.93e1.51)
day 1.49 (0.85e2.63)
ay 1.77 (0.79e3.98)
K 1.00 Age, smoking
habit, alcohol,
education,
baseline diseases
y 0.78 (0.56e1.07)
day 1.16 (0.93e1.45)
ay 1.42 (1.11e1.81)
L y 1.00 Age, BMI,
hypertension,
smoking habit,
exercise, other
diseases,
dietary pattern
day 1.33 (1.15e1.54)
ay 1.35 (1.08e1.68)
K 1.00 Age, gender, BMI,
smoking habit,
alcohol, education
y 0.99 (0.67e1.46)
day 1.17 (0.87e1.57)
ay 1.35 (0.97e1.89)
K 1.00 Age, cholesterol,
smoking habit,
hypertension,
diabetes, BMI
day 1.70 (0.78e3.68)
day 3.02 (1.37e6.65)
ay 2.94 (1.27e6.81)
G day 1.00 Age, smoking
habit, alcohol,
hypertension,
triglycerides
day 1.0 (0.7e1.4)
ay 0.6 (0.3e1.0)
H 1.00 Age, diastolic
blood pressure,
cholesterol,
smoking habit,
BMI, social class,
education
s/day 1.20 (0.87e1.64)
s/day 1.17 (0.83e1.65)
s/day 1.16 (0.81e1.66)
day 1.49 (0.89e2.47)
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ource, year Country Total
N/no. of
cases
Mean Follow-up
(years)
Age at
baseline
(years)
Gender Outcome Coffee
consumptio
aCroix
et al. 1986 [20]
USA 1040/47 19e35 19e49 M CHD None
1e2 cups/
3e4 cups/
5 cups/d
latsky
et al. 1990 [43]
USA 101774/1914 5 59a M/F MI None
<1 cup/da
1e3 cups/
4 cups/d
indsted
et al. 1992 [14]
USA 9484/647 15 50e99 M CHD <1 cup/da
1e2 cups/
3 cups/d
latsky
et al. 1993 [24]
USA 128934/433 3e10 <50; 60 (not
otherwise
indicated)
M/F MI None
<1 cup/da
1e3 cups/
4 cups/d
lag
et al. 1994 [4]
USA 933/95 28e44 26.3a M CHD None
1e2 cups/
3e4 cups/
>5 cups/d
yntelberg
et al. 1995 [17]
Denmark 2975/184 6 53e74 M CHD 1e4 cups/
5e8 cups/
9 cups/d
art and
Smith, 1997 [25]
Scotland 2686/282 21 35e64 M CHD None
0.5e1 cup
1.5e2 cup
2.5e4 cup
>4.5 cups/
CHD <1 cup/month 1.00 Age, smoking
habit, BMI,
diabetes,
hypertension,
hypercholesterolemia,
family history
of MI, alcohol,
physical activity,
menopausal status,
hormone therapy,
aspirin use
1/month-4
cups /week
0.97 (0.83e1.14)
5e7 cups/week 1.02 (0.90e1.17)
2e3 cups/day 0.84 (0.74e0.97)
4e5 cups/day 0.99 (0.83e1.17)
6 cups/day 0.87 (0.68e1.11)
CHD <1 cup/month 1.00 Age, smoking
habit, BMI, diabetes,
hypertension,
hypercholesterolemia,
family history of MI,
alcohol, physical
activity, aspirin use
1/monthe4
cups /week
1.04 (0.91e1.17)
5e7 cups/week 1.02 (0.91e1.15)
2e3 cups/day 0.97 (0.86e1.11)
4e5 cups/day 1.07 (0.88e1.31)
6 cups/day 0.72 (0.49e1.07)
CHD None 1.00 Age, smoking habit,
BMI, waist-hip ratio,
education, physical
activity, alcohol,
use of estrogens,
energy intake,
multivitamin
supplements, dietary
pattern
<1 cups/day 0.85 (0.68e1.06)
1e3 cups/day 0.76 (0.64e0.91)
4e5 cups/day 0.81 (0.66e0.99)
6 cups/day 0.87 (0.69e1.04)
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et al. 2006 [27]
(final data of Willett
et al. 1996 [18])
USA 84488/2254 20 34e59 F
Lopez-Garcia
et al. 2006 [27]
(final data of
Grobbee et al. [16])
USA 44005/2173 14 40e84 M
Andersen
et al. 2006 [28]
U.S.A 27312/1411 15 55e69 F
MI, myocardial infarction; CHD, coronary heart disease; BMI, body mass index.
a Not otherwise indicated in the study.
216 F. Sofi et al.(if present) would explain the observed associa-
tions, we calculated fail-safe numbers that indi-
cated the number of studies with null results that
would need to be added to the meta-analysis in
order to reduce the overall level of significance of
the observed result to that of non-significance [66].
Results
Caseecontrol studies
Characteristics of the caseecontrol studies in-
cluded in themeta-analysis are described in Table 1.
The vast majority of these studies had myocardial
infarction as the primary outcome. Fig. 1 shows the
results of caseecontrol studies for different levels
of coffee consumption, compared with the lowest
level of coffee consumption. First, we compared
the highest category of coffee consumption with
the reference category. The summary OR from
a random-effect model showed that individuals
who consumed a high amount of coffee per day
had an increased risk of developing CHD (OR 1.83;
95% CI 1.49e2.24; P < 0.0001) (Fig. 1a). However,
the P value for heterogeneity was 0.02. Studies by
Sesso et al. [22] and by Brown et al. [23] contributed
substantially to the heterogeneity in this result.
Nevertheless, exclusion of these studies from the
analysis did not change the significant association
found between the highest category of coffee con-
sumption and CHD (OR 2.03; 95% CI 1.77e2.33;
P < 0.0001); P for heterogeneity ¼ 0.46.
We subsequently compared the second highest
category of coffee consumption versus the refer-
ence category, showing that the overall effect of
a moderately high consumption of coffee remained
significantly associated with the occurrence of
CHD (OR 1.33; 95% CI 1.04e1.71; P < 0.0001); P
for heterogeneity < 0.0001 (Fig. 1b). Exclusion of
the study by Brown et al. [23], which accounted
for the significant heterogeneity demonstrated in
this model, did not influence the overall result
(OR 1.42; 95% CI 1.18e1.71; P ¼ 0.002); P for
heterogeneity ¼ 0.06.
Finally, as the third highest category of coffee
consumption (2 cups per day) was analysed, the
significant association between coffee consump-
tion and CHD found for the other categories was
not present (OR 1.03; 95% CI 0.87e1.21; P ¼ 0.76)
(Fig. 1c). The P for heterogeneity was significant
(P ¼ 0.01); however, after exclusion of the study
by Brown et al. [23], which accounted for signifi-
cant heterogeneity in the model, the results
did not change substantially (OR 1.07; 95% CI
0.89e1.29; P ¼ 0.46); P for heterogeneity ¼ 0.06.Cohort studies
Characteristics of the cohort studies included in
the meta-analysis are described in Table 2. In con-
trast to caseecontrol studies, many of the cohort
prospective studies reported CHD as the primary
outcome and involved male subjects.
In 10 cohort studies, including a total of 403,631
participants followed for between 3 and 44 years,
the cumulative RR for all cohort studies was 1.16
(95% CI 0.95e1.41; P ¼ 0.14) for the highest cate-
gory of coffee consumption (Fig. 2a), thus not
showing an association between high coffee con-
sumption and CHD. However, the analysis showed
a significant heterogeneity across all studies
(P ¼ 0.0008), mainly due to the studies by Klatsky
et al. [35] and Lindsted et al. [14], which ac-
counted for the largest RRs. By excluding these
studies from the analysis, the result was confirmed
(RR 1.11; 95% CI 0.88e1.41; P ¼ 0.38); P for
heterogeneity ¼ 0.08.
We analysed the second highest category of
coffee consumption, representing a moderate
daily intake of coffee, and the summary RR did
not reveal a significant association between coffee
consumption and CHD (RR 1.05; 95% CI 0.90e1.22;
P ¼ 0.57) (Fig. 2b). The result was confirmed after
exclusion from the analysis of the study by Klag
et al. [4], which accounted for the heterogeneity
in the model (RR 1.04; 95% CI 0.89e1.20; P ¼ 0.4).
Finally, we performed the analysis for the third
highest category of coffee consumption (2 cups
per day), and found that the cumulative RR for
all cohort studies was 1.04 (95% CI 0.90e1.19;
P ¼ 0.60) (Fig. 2c). A significant heterogeneity
across all studies was reported (P ¼ 0.002); how-
ever, after eliminating from the model the study
by Lindsted et al. [14], which accounted for signif-
icant heterogeneity, the result did not differ sub-
stantially (RR 0.99; 95% CI 0.87e1.12; P ¼ 0.85); P
for heterogeneity ¼ 0.34.
Characteristics of the study population
Similar associations for coffee consumption cate-
gories among US compared with European casee
control and cohort studies were seen (Table 3). In
contrast, cohort prospective studies published
before the median year of publication of all of
the studies included, report an association with
CHD while those published after the median year.
Finally, no significant differences, according to
fatal and non-fatal events as well as to the number
of years of follow-up within cohort studies, were
observed.
Coffee and coronary heart disease 217Figure 1 Odds ratios for the association between coffee consumption and coronary heart disease among casee
control studies. (a) Highest category of coffee consumption (>4 cups/day) vs. reference category (none or <1 cup/day).
(b) Second highest category of coffee consumption (3e4 cups/day) vs. reference category (none or <1 cup/day).
(c) Third highest category of coffee consumption (2 cups/day) vs. reference category (none or <1 cup/day).
218 F. Sofi et al.Figure 2 Relative risks for the association between coffee consumption and coronary heart disease among cohort pro-
spective studies. (a) Highest category of coffee consumption (>4 cups/day) vs. reference category (none or <1 cup/
day). (b) Second highest category of coffee consumption (3e4 cups/day) vs. reference category (none or <1 cup/
day). (c) Third highest category of coffee consumption (2 cups/day) vs. reference category (none or <1 cup/day).
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We explored the potential for publication bias
using funnel plots of effect size versus standard
error. The plots for all the categories of coffee
consumption among caseecontrol studies were
broadly symmetrical, consistent with the conclu-
sion that there was no major publication bias,
whereas slightly asymmetrical plots for cohort
studies were observed. Thus, we calculated the
number of studies with null results that would
need to be added to the meta-analysis to reduce
the overall observed associations to a level of non-
significance, i.e. the fail-safe number. This was
228 for the highest level of coffee consumption
among caseecontrol studies, and nine for the
highest category of consumption within cohort
studies. Hence, the number was robust for casee
control studies only, according to the commonly
used criterion that an analysis requires a fail-safe
number greater than 5n þ 10 (where n is the orig-
inal number of studies in the analysis). However,
by performing sensitivity analyses among cohort
studies, it could be observed that smaller cohort
studies published before 1995 are the principle de-
terminants of the low fail-safe number reported.
Decaffeinated coffee
Decaffeinated coffee was examined separately in
four caseecontrol studies [5,8,9,22] and three
cohort studies [27,28] included in the meta-analy-
sis. In addition, a paper by La Vecchia et al. [44]
eliminated from the previous analysis since it in-
vestigated only decaffeinated coffee, was intro-
duced into the present model at this point.
Within caseecontrol studies consumption of decaf-
feinated coffee, in terms of both the highest and
lowest categories (>4 cups per day and 2 cups
per day, respectively), was not significantly associ-
ated with an increased risk of CHD (OR 1.87; 95% CI
0.96e3.46; P ¼ 0.07 and OR 1.05; 95% CI 0.85e
1.29; P ¼ 0.7, respectively); heterogeneity across
the studies was also not significant. Similarly, no
significant association between decaffeinated cof-
fee consumption and CHD was reported for cohort
studies, at both categories of consumption (RR
1.10; 95% CI 0.90e1.34; P ¼ 0.33 and RR 1.00;
95% CI 0.93e1.07; P ¼ 0.90, respectively).
Discussion
The present meta-analysis, performed in 13 casee
control and 10 cohort studies, with an overall
220 F. Sofi et al.incorporated population of more than 430,000
subjects and 18,000 CHD cases, shows no clear
indication that coffee consumption determines an
increased risk of CHD. An association among the
highest categories (mainly >2 cups per day) of
coffee drinking and CHD within caseecontrol stud-
ies has been reported. However, this result was not
confirmed among cohort prospective studies with
a follow-up period ranging from 3 to 44 years. Nev-
ertheless, it should be noted that among cohort
prospective studies, publication bias cannot be
excluded because of the low fail-safe number
assessed. Finally, decaffeinated coffee, analysed
in four caseecontrol and three cohort studies,
showed no significant association between both
the highest and the third highest categories of cof-
fee consumption and an increased risk of CHD, with
respect to the reference category.
During the past three decades, the relationship
between coffee drinking and the occurrence of
CHD has been assessed in numerous studies, with
conflicting results [1e28]. Some studies reported
a positive association between coffee intake and
CHD [1e14], whereas others did not [15e28], possi-
bly suggesting that the increase in the susceptibil-
ity of coronary disease found in previous studies
was the result of either an unhealthy lifestyle pat-
tern associated with coffee consumption, or of
some detrimental acute effects of coffee intake
on CHD-related risk factors. Coffee has been widely
investigated for its effects on the cardiovascular
system, and the biological plausibility of an in-
creased risk of CHD with a high intake of coffee
has been identified through its influence on blood
pressure, serum lipids, inflammatory markers, and
homocysteinedsome of the most important risk
factors for CHD. Administration of coffee has
been demonstrated to significantly raise blood
pressure in men [67], but not in women [68]. More-
over, coffee has been reported to raise inflamma-
tory markers and lipid levels, although the effect
on lipids is probably influenced by the brewing
method, being higher for the boiled compared to
the filtered method [36,69]. Finally, some studies
during recent years have reported a significant in-
fluence of coffee beverages on plasma levels of ho-
mocysteine [70]. On the other hand, a protective
effect of coffee consumption on the occurrence
of diabetes has been suggested by a recent meta-
analysis, which showed a significant inverse associ-
ation between habitual coffee consumption and
the risk of type 2 diabetes [71]. Similarly, coffee
consumption has been found to be associated
with a reduced risk of chronic liver disease [72].
Three comprehensive meta-analyses investigat-
ing coffee consumption in relation to CVD werepublished previously, reporting conflicting find-
ings. In 1992, Myers et al. [29] reported that
in 11 prospective cohort studies there was no
evidence for an association between coffee con-
sumption and the development of CHD; whereas
in 1993, Greenland et al. [30] analysed eight
caseecontrol and 14 cohort studies, and observed
that subjects drinking more than five cups per
day had an increased risk of myocardial infarction
if compared to non-drinkers, but only among
caseecontrol studies. On the other hand, another
meta-analysis by Kawachi et al. [31] in 1994 ass-
essing eight caseecontrol and 15 cohort studies,
concluded that a moderate-to-high coffee con-
sumption was not significantly associated with an
increased risk of coronary death or heart attack.
The results of these meta-analyses are in keeping
with our findings, since they all show no associa-
tion between coffee consumption and the occur-
rence of CHD among cohort prospective studies,
whereas a significant association is reported with
regard to caseecontrol studies. This divergence
of results according to the different type of studies
analysed could be ascribed to several factors: first,
caseecontrol studies suffer from recall bias, which
may explain the positive association shown with
the disease as individuals who developed CHD are
more likely to over-report coffee intake than are
healthy controls. In addition, caseecontrol studies
are not likely to include fatal events, whereas co-
hort studies usually do. This equates to a substan-
tial difference in outcome measures between the
two types of studies. Indeed, a recent analysis in
the Iowa Women’s Study suggests that coffee
may even be protective for fatal events, possibly
contributing to differences between cohort and
caseecontrol studies [28]. Furthermore, caffeine
has mainly adverse acute effects on the cardiovas-
cular system, thus explaining the association with
CHD found in caseecontrol but not in follow-up
studies. Alternatively, some of the discrepancies
among studies on coffee and CHD could derive
from the complex, heterogeneous, and controver-
sial nature of coffee beverages. There are a wide
variety of beverages containing caffeine, and the
difference in terms of caffeine content between
different types of coffees is extremely significant.
In the present meta-analysis we used the estima-
tion of coffee intake as cups consumed per day.
This is the unit of measure generally reported in
studies considering beverages like coffee and
tea. However, there is no standard definition of
cup size, and volumes may vary considerably
among studies. Similarly, caffeine content is likely
to be substantially different among the different
kinds of coffee [73]. For instance, espresso coffee,
Coffee and coronary heart disease 221commonly used in Italy, contains 35e45% less caf-
feine than percolated and boiled coffees, widely
used in all other countries. Moreover, the effect
of the different types of coffee on blood determi-
nants related to CHD vary considerably: boiled cof-
fee has been found extensively to be associated
with an increase in serum cholesterol, whereas
no association has been shown for coffee prepared
by the filter process [36]. In our meta-analysis we
did not find any significant differences when taking
into account the regions of origin of the studies or
the different types of coffees usually consumed
across the different countries. In keeping with
our results, a previous meta-analysis by Myers
et al. showed no association between the method
of coffee preparation and the occurrence of CHD
[29]. Another possible explanation for the discrep-
ancies in results could be related to the wide inter-
individual variability in coffee metabolism present
among the population as a whole. Interestingly, it
has been reported recently that a genetic variant
in the cytochrome P450 1A2 gene, which accounts
for approximately 95% of caffeine metabolism,
plays an important role in the association between
coffee consumption and the occurrence of myocar-
dial infarction [74]. Moreover, it has been shown
that subjects carrying this genetic variant had
slow caffeine metabolism, and consequently an in-
creased risk for CHD. This finding suggests an
environmentalegenetic interaction for coffee con-
sumption, which may further explain the conflict-
ing results of studies investigating coffee intake
in relation to CHD. Publication bias is present
within cohort prospective studies and is a main
limitation in the present meta-analysis, especially
considering the low fail-safe numbers obtained. On
the other hand, sensitivity analyses performed ac-
cording to the main characteristics of the studies
demonstrated a significant influence of smaller
and older studies in determining such bias.
In conclusion, the present meta-analysis indi-
cates that, in general, coffee consumption is not
associated with an increased risk of CHD, whereas
a significant association of CHD with high consump-
tion of coffee is reported among caseecontrol
studies. Furthermore, decaffeinated coffee seems
not to be associated with an increased risk of CHD,
despite the fact that only a few, limited studies are
available where decaffeinated coffee is evaluated
separately. The influence of coffee on the health of
the people is considered to be of great significance
since coffee is one of the most commonly con-
sumed beverages in Western countries. Hence,
these results appear of extreme importance in
clarifying the relationship between coffee con-
sumption and CHD.Acknowledgments
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